In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Bank Leumi (TASE: LUMI) led the market today, falling 1.02% on the day's biggest trading turnover. Bank Hapoalim (TASE: POLI) fell 1.37%, Mizrahi Tefahot Bank fell 0.53% and Israel Discount Bank (TASE ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

This stock has stumbled, but long-term investors may want to lace up and run toward this dip before it sprints higher.

In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...

The Bank of Israel set the representative shekel-dollar rate up 0.028% today from Wednesday, at NIS 3.542/$, and the representative shekel-euro rate was set 0.089% higher at NIS 3.697/€.

Corcept Therapeutics (CORT) stock turned lower after a group of insurers sued the company for blocking Teva's (TEVA) launch of generic Korlym. Read more here.

Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...

Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...